Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Amgen

Learn more at ClinicalTrials.gov

Email for more information: MISC-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.